Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19

NCT ID: NCT04426253

Last Updated: 2020-06-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-05

Study Completion Date

2021-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to identify environmental factors and genetic (gene mutation and gene expression) changes, which influencing the course of the disease the new type of coronavirus infection COVID-19 in patients nationwide in a multicenter study.

At first in the study will be performed 200 patients, selected for a homogeneous groups on the basis of the patient's anamnestic data, genetic testing.

Following the interim analysis, based on the results, another 800 people are planned to involve.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Sars-CoV2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* confirmed covid 19 infection

Exclusion Criteria

* informed refusal
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Szeged University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Márta Széll, MD, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Szeged, Department of Medical Genetics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Pécs 1st Department of Internal Medicine Intensive Care Unit

Pécs, , Hungary

Site Status

University of Pécs First Department of Internal Medicine

Pécs, , Hungary

Site Status

University of Pécs Infection Department of the Coronavirus Center

Pécs, , Hungary

Site Status

University of Pécs Institute of Laboratory Medicine

Pécs, , Hungary

Site Status

University of Pécs Szentágotahi Research Centre

Pécs, , Hungary

Site Status

University of Pécs Szentágothai Research Centre Genomics and Bioinformatics Core Facility

Pécs, , Hungary

Site Status

University of Szeged Szentágothai Research Centre Virology Research Group

Pécs, , Hungary

Site Status

University of Szeged Department of Anaesthesiology And Inthensive Therapy

Szeged, , Hungary

Site Status

University of Szeged Department of Dermatology and Allergology

Szeged, , Hungary

Site Status

University of Szeged Department of Medical Biology

Szeged, , Hungary

Site Status

University of Szeged Department of Paediatrics

Szeged, , Hungary

Site Status

University of Szeged First Department of Medicine

Szeged, , Hungary

Site Status

University of Szeged Institute of Clinical Microbiology

Szeged, , Hungary

Site Status

University of Szeged Institute of Medical Microbiology and Immunobiology

Szeged, , Hungary

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hungary

References

Explore related publications, articles, or registry entries linked to this study.

Danis J, Janovak L, Guban B, Goblos A, Szabo K, Kemeny L, Bata-Csorgo Z, Szell M. Differential Inflammatory-Response Kinetics of Human Keratinocytes upon Cytosolic RNA- and DNA-Fragment Induction. Int J Mol Sci. 2018 Mar 8;19(3):774. doi: 10.3390/ijms19030774.

Reference Type BACKGROUND
PMID: 29518010 (View on PubMed)

Chiu RW, Tang NL, Hui DS, Chung GT, Chim SS, Chan KC, Sung YM, Chan LY, Tong YK, Lee WS, Chan PK, Lo YM. ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. Clin Chem. 2004 Sep;50(9):1683-6. doi: 10.1373/clinchem.2004.035436. No abstract available.

Reference Type BACKGROUND
PMID: 15331509 (View on PubMed)

Pinheiro DS, Santos RS, Jardim PCBV, Silva EG, Reis AAS, Pedrino GR, Ulhoa CJ. The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: A genetic association study in Brazilian patients. PLoS One. 2019 Aug 20;14(8):e0221248. doi: 10.1371/journal.pone.0221248. eCollection 2019.

Reference Type BACKGROUND
PMID: 31430320 (View on PubMed)

Scepanovic P, Alanio C, Hammer C, Hodel F, Bergstedt J, Patin E, Thorball CW, Chaturvedi N, Charbit B, Abel L, Quintana-Murci L, Duffy D, Albert ML, Fellay J; Milieu Interieur Consortium. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med. 2018 Jul 27;10(1):59. doi: 10.1186/s13073-018-0568-8.

Reference Type BACKGROUND
PMID: 30053915 (View on PubMed)

Dean L. Abacavir Therapy and HLA-B*57:01 Genotype. 2015 Sep 1 [updated 2025 Apr 21]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK315783/

Reference Type BACKGROUND
PMID: 28520363 (View on PubMed)

Danis J, Goblos A, Gal B, Sulak A, Farkas K, Torok D, Varga E, Korom I, Kemeny L, Szell M, Bata-Csorgo Z, Nagy N. Nuclear Factor kappaB Activation in a Type V Pityriasis Rubra Pilaris Patient Harboring Multiple CARD14 Variants. Front Immunol. 2018 Jul 3;9:1564. doi: 10.3389/fimmu.2018.01564. eCollection 2018.

Reference Type BACKGROUND
PMID: 30018619 (View on PubMed)

Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, Wen F, Huang X, Ning G, Wang W. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020 Feb 24;6:11. doi: 10.1038/s41421-020-0147-1. eCollection 2020. No abstract available.

Reference Type BACKGROUND
PMID: 32133153 (View on PubMed)

Teng DH, Chen Y, Lian L, Ha PC, Tavtigian SV, Wong AK. Mutation analyses of 268 candidate genes in human tumor cell lines. Genomics. 2001 Jun 15;74(3):352-64. doi: 10.1006/geno.2001.6551.

Reference Type BACKGROUND
PMID: 11414763 (View on PubMed)

Paoloni-Giacobino A, Chen H, Peitsch MC, Rossier C, Antonarakis SE. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics. 1997 Sep 15;44(3):309-20. doi: 10.1006/geno.1997.4845.

Reference Type BACKGROUND
PMID: 9325052 (View on PubMed)

Lin M, Tseng HK, Trejaut JA, Lee HL, Loo JH, Chu CC, Chen PJ, Su YW, Lim KH, Tsai ZU, Lin RY, Lin RS, Huang CH. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet. 2003 Sep 12;4:9. doi: 10.1186/1471-2350-4-9.

Reference Type BACKGROUND
PMID: 12969506 (View on PubMed)

Manczinger M, Boross G, Kemeny L, Muller V, Lenz TL, Papp B, Pal C. Pathogen diversity drives the evolution of generalist MHC-II alleles in human populations. PLoS Biol. 2019 Jan 31;17(1):e3000131. doi: 10.1371/journal.pbio.3000131. eCollection 2019 Jan.

Reference Type BACKGROUND
PMID: 30703088 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COVID19_HUNGEN_001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Omics Gaucher Study: Multiomic Approach
NCT05526664 ACTIVE_NOT_RECRUITING